Skip to main content
    T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.19
    +0.01 (+3.41%)

    Market Cap: $14.23M

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    +3.90%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.23 - $-0.08
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.21+15.1%
    60d ago$-0.21+15.1%
    30d ago$-0.22+16.1%
    7d ago$-0.180.0%
    Current$-0.18
    Revenue Consensus
    $471500
    Range$0 - $1M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.34 - $-0.07
    4 analysts
    Revenue Consensus
    $-2550250
    Range$-3438500 - $-471500
    4 analysts
    Last 12 of 22 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.23$-0.34 - $-0.07--4--
    Sep 26EST
    		-$-0.18$-0.23 - $-0.08--4
    2
    2
    30d
    		-
    Jun 26
    Reported Aug 12
    		$-0.23$-0.29$-0.30 - $-0.28+20.69%Beat4
    0
    4
    30d
    		+17.9%
    Mar 26
    Reported May 6
    		$-0.22$-0.16$-0.18 - $-0.13-37.50%Miss4
    3
    0
    30d
    		+15.4%
    Dec 25
    Reported Mar 4
    		$-0.18$-0.27$-0.42 - $-0.19+32.61%Beat5
    1
    2
    30d
    		+40.0%
    Sep 25
    Reported Nov 12
    		$-0.28$-0.33$-0.57 - $-0.24+15.15%Beat6
    1
    1
    30d
    		-12.0%
    Jun 25
    Reported Aug 12
    		$-0.28$-0.32$-0.58 - $-0.22+12.50%Beat6
    2
    1
    30d
    		+0.0%
    Mar 25
    Reported May 6
    		$-0.26$-0.28$-0.32 - $-0.21+7.14%Beat5
    1
    0
    30d
    		+18.8%
    Dec 24
    Reported Mar 5
    		$-0.30$-0.29$-0.30 - $-0.24-3.45%Miss5
    2
    0
    30d
    		-42.9%
    Sep 24
    Reported Nov 12
    		$-0.25$-0.29$-0.34 - $-0.24+13.79%Beat7
    No revisions (30d)
    		-4.2%
    Jun 24
    Reported Aug 12
    		$-0.28$-0.28$-0.35 - $-0.23+0.00%Beat7
    No revisions (30d)
    		+45.1%
    Mar 24
    Reported May 13
    		$-0.32$-0.24$-0.27 - $-0.24-33.33%Miss4
    No revisions (30d)
    		+65.6%
    Dec 23
    Reported Mar 6
    		$-0.21$-0.29$-0.44 - $-0.26+27.59%Beat6
    No revisions (30d)
    		+73.1%
    Sep 23
    Reported Nov 9
    		$-0.24$-0.44$-0.54 - $-0.25+45.45%Beat5
    No revisions (30d)
    		+64.2%

    Key Metrics

    Valuation
    P/E Ratio-0.21EV/EBITDAN/A
    Price/FCF-0.21xFCF Yield-484.80%
    Profitability
    Profit Margin0.00%Operating Margin-2901.00%
    ROE-95.80%ROIC-93.55%
    Financial Health
    Debt/Equity0.47xInterest Coverage-43.22x
    Current Ratio3.37xQuick Ratio3.37x
    Trading Statistics
    Beta1.19Avg Volume549.40K
    52-Week High$1.4752-Week Low$0.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.19
    SMA 20$0.21
    SMA 50$0.30
    SMA 200$0.83
    EMA 10$0.19
    EMA 20$0.22
    EMA 50$0.33
    EMA 200$0.76

    MACD

    Line: -0.04Signal: -0.05Hist: 0.01

    ADX

    ADX: 55.6+DI: 10.3-DI: 28.8

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$0.21

    Bollinger Bands

    Upper Band$0.24
    Lower Band$0.17
    %B Position3794%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    35.9

    Momentum Oscillators

    Stoch %K31.4
    Stoch %D29.3
    Williams %R-73.0
    ROC (10d)-7.5%
    Momentum-0.02
    CCI (20d)-83.6
    MFI (14d)38.6

    Volatility Measures

    ATR (14d)$0.02(13.1%)
    StdDev (20d)0.02
    Hist Vol113.1%(High)

    Volume Flow

    VWAP$0.18
    OBV-27.0M
    AD Line-33.1M
    CMF (20d)0.005

    Volume Metrics

    Avg Vol (20d)483.9K
    Vol Ratio0.6x
    VWMA (20d)$0.21

    Pivot Points

    R3$0.23
    R2$0.22
    R1$0.20
    Pivot Point$0.19
    S1$0.17
    S2$0.15
    S3$0.13

    Advanced Oscillators

    TSI-37.99
    Ultimate Osc47.8
    KST-323.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.05M$982,000$2.57M$2.51M$3.08M$2.17M$665,000$1.05M$536,000$566,000$7.21M$3.89M
    Cost of Revenue$0$0$723,000$0$0$0$711,000$0$0$0$1.28M$0
    Gross Profit$1.05M$982,000$2.57M$2.51M$3.08M$2.17M$665,000$1.05M$536,000$566,000$7.21M$3.89M
    Operating Expenses$31.54M$30.12M$26.43M$39.56M$41.73M$38.42M$37.38M$33.67M$34.65M$31.94M$28.57M$28.64M
    R&D$23.40M$21.90M$20.04M$31.69M$32.63M$29.79M$29.35M$26.26M$26.88M$24.86M$22.41M$22.74M
    SG&A$8.14M$8.22M$6.39M$7.87M$9.10M$8.63M$8.02M$7.41M$7.77M$7.08M$6.16M$5.89M
    Operating Income$-30,493,000$-29,139,000$-23,858,000$-37,052,000$-38,653,000$-36,250,000$-36,712,000$-32,622,000$-34,114,000$-31,373,000$-21,357,000$-24,748,000
    Interest Income$833,000$1.16M$1.58M$2.04M$2.39M$2.80M$2.78M$3.69M$3.40M$2.19M$2.60M$2.73M
    Interest Expense$699,000$689,000$702,000$699,000$689,000$679,000$1.87M$958,000$952,000$959,000$852,000$982,000
    Income Before Tax$-30,359,000$-28,666,000$-22,977,000$-35,710,000$-36,952,000$-34,127,000$-35,809,000$-29,887,000$-31,661,000$-30,142,000$-19,613,000$-22,997,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-30,359,000$-28,666,000$-22,977,000$-35,710,000$-36,952,000$-34,127,000$-35,809,000$-29,887,000$-31,661,000$-30,142,000$-19,613,000$-22,997,000
    EBITDA$-29,794,000$-28,446,000$-23,135,000$-36,285,000$-37,955,000$-35,572,000$-36,001,000$-31,595,000$-32,998,000$-30,119,000$-20,077,000$-23,462,000
    EBIT$-30,493,000$-29,139,000$-23,858,000$-37,052,000$-38,653,000$-36,250,000$-36,712,000$-32,622,000$-34,114,000$-31,373,000$-21,357,000$-24,748,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TCRX

    News

    TScan Therapeutics, Inc. (TCRX) Seasonal returns chart

    The article provides a seasonal returns chart for TScan Therapeutics, Inc. (TCRX), showing the average monthly price return from 2021 to 2026. It also displays current stock information...

    Yahoo Finance Australia•10/31/26•Neutral

    Form DEF 14A Tscan Therapeutics Inc For: 26 October By Investing.com

    This article announces the filing of Form DEF 14A by Tscan Therapeutics Inc. for October 26, as reported by Investing.com. It indicates that the document is available for viewing and is related to the company's financial...

    Investing.com South Africa•10/27/26•Neutral

    TScan Therapeutics Proposes Reverse Stock Split, Seeks Shareholder Approval

    TScan Therapeutics, Inc. has announced a Special Meeting of Stockholders for November 20, 2026, to vote on a proposed reverse stock split of its common shares...

    Kalkine Media•10/26/26•Somewhat-Bearish

    Form DEF 14A Tscan Therapeutics Inc For: 26 October By Investing.com

    The article reports on the filing of Form DEF 14A by Tscan Therapeutics Inc. The filing is related to October 26 and is primarily a notice of the document's existence rather than a detailed analysis of its contents. It...

    Investing.com Canada•10/26/26•Neutral

    Form DEF 14A TScan Therapeutics, Inc. For: Nov 20

    TScan Therapeutics, Inc. has filed a definitive proxy statement (DEF 14A) for a Special Meeting of Stockholders on November 20...

    StreetInsider•10/26/26•Neutral

    TCRX Valuation and Fair Value

    P/E
    -0.2x
    P/FCF
    -0.2x
    P/B
    0.4x
    See GNG's fair value

    TCRX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -2901.0%
    Net margin
    0.0%
    ROIC
    -93.5%
    ROE
    -95.8%
    FCF yield
    -484.8%

    TCRX Competitors

    CompanyTicker
    Cytosorbents CrpCTSO
    Biocardia IncBCDA
    MDxHealth SAMDXH
    Psyence Biomedical Ltd. Common SharesPBM
    Marker Therapeutics IncMRKR
    Dyadic International IncDYAI
    Neuphoria Therapeutics IncNEUP
    Quantum BioPharma Ltd.QNTM

    Sector: Healthcare

    TCRX Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    TCRX Bull Case vs Bear Case

    Bull case

    • TCRX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 83.3% of TCRX's analyst ratings are Buy or Strong Buy.

    Bear case

    • TCRX's quarterly revenue changed -65.8% year over year.

    TCRX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    7.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.18
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 2 down

    TCRX Earnings Date

    TCRX reports Nov 11, 2026. The date is confirmed.

    TCRX ETF Holders

    GNG tracks 4 ETFs that hold TCRX. The largest weights:

    1. abrdn Healthcare Investors (HQH), 0.01% of the fund
    2. BlackRock Health Sciences Trust (BME), 0.01% of the fund
    3. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    4. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    Open the ETF Stock Exposure tool for TCRX

    See insider activity

    Frequently Asked Questions About TCRX

    When does TCRX report earnings?

    Tscan Therapeutics Inc (TCRX) is confirmed to report earnings on Nov 11, 2026.

    Does TCRX pay dividends?

    Tscan Therapeutics Inc (TCRX) does not currently pay a regular dividend.

    What is TCRX's market cap?

    Tscan Therapeutics Inc (TCRX) has a market capitalization of $14.23M with a current stock price of $0.19.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In